Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Maryland: - UM Upper Chesapeake Hematology and Oncology - Aberdeen — Aberdeen, Maryland
- Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Mercy Medical Center — Baltimore, Maryland
- Greater Baltimore Medical Center — Baltimore, Maryland
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Maryland: - UM Upper Chesapeake Hematology and Oncology - Aberdeen — Aberdeen, Maryland
- Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
- UPMC Western Maryland — Cumberland, Maryland
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Maryland: - Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Greater Baltimore Medical Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- Kaiser Permanente-Woodlawn Medical Center — Baltimore, Maryland
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Greater Baltimore Medical Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- Saint Agnes Hospital — Baltimore, Maryland
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Maryland: - UM Upper Chesapeake Medical Center — Bel Air, Maryland
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute — Baltimore, Maryland
- MedStar Good Samaritan Hospital — Baltimore, Maryland
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in Maryland: - UM Upper Chesapeake Hematology and Oncology - Aberdeen — Aberdeen, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Greater Baltimore Medical Center — Baltimore, Maryland
- UM Upper Chesapeake Medical Center — Bel Air, Maryland
- University of Maryland Shore Medical Center at Easton — Easton, Maryland
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Maryland: - Mercy Medical Center — Baltimore, Maryland
- Ascension St. Agnes Hospital — Baltimore, Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
- Maryland Oncology Hematology, P.A. — Columbia, Maryland
Phase 3 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…
Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in Maryland: - American Oncology Partners, PA — Bethesda, Maryland
- James M Stockman Cancer Institute — Frederick, Maryland
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Sites in Maryland: - Maryland Oncology Hematology P.A. — Annapolis, Maryland
- Mfsmc-Hjwci — Baltimore, Maryland
- Maryland Oncology Hematology P.A. — Bethesda, Maryland
- Maryland Oncology Hematology P.A. — Columbia, Maryland
- Maryland Oncology Hematology P.A. — Germantown, Maryland
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in Maryland: - The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A. — Bethesda, Maryland
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Maryland: - Mercy Medical Center - Baltimore ( Site 0015) — Baltimore, Maryland
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Maryland: - Velocity Clinical Research — Annapolis, Maryland
- University of Maryland — Baltimore, Maryland
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Maryland: - Clinical Trial Site — Annapolis, Maryland
- Clinical Trial Site — Baltimore, Maryland
- Clinical Trial Site — Baltimore, Maryland
- Clinical Trial Site — Catonsville, Maryland
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins — Baltimore, Maryland
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in Maryland: - Johns Hopkins Kimmel Cancer Center — Baltimore, Maryland
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Sites in Maryland: - Johns Hopkins Hospital — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Maryland: - USOR Maryland Oncology Hematology — Rockville, Maryland
Phase 1, Phase 2 Recruiting Industry
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Sponsor: AstraZeneca
NCT ID: NCT05123482
Sites in Maryland: - Research Site — Baltimore, Maryland
Phase 2 Recruiting Industry
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…
Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Maryland: - Johns Hopkins University — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in…
Sponsor: Yale University
NCT ID: NCT06923527
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center at John Hopkins — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropr…
Sponsor: AtlasMedx, Incorporated
NCT ID: NCT04503265
Sites in Maryland: - Johns Hopkins — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
This is a research study to test the safety and effectiveness of using the drug alpelisib together with chemotherapy (nab-paclitaxel) and a drug called L-NMMA in patients with HER2 negative metastatic or locally advanced metaplastic breast…
Sponsor: The Methodist Hospital Research Institute
NCT ID: NCT05660083
Sites in Maryland: - National Institute of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting Academic/Other
This study is a prospective evaluation of systemic, intravenous high-dose methotrexate (HD-MTX, 8 g/m2) in patients with triple negative, HER2-positive, and hormone refractory breast cancer with leptomeningeal metastasis (LMD) with or with…
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT02422641
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will …
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06245889
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland